Outcomes of hypertrophic cardiomyopathy in Japanese children: a retrospective cohort study

Heart Vessels. 2022 Jun;37(6):1075-1084. doi: 10.1007/s00380-021-01989-7. Epub 2021 Nov 19.

Abstract

There has been no multicenter study on the prognosis of pediatric hypertrophic cardiomyopathy (HCM) in Japan. Therefore, we conducted a retrospective multicenter observational study on the long-term survival rate in patients diagnosed with HCM under the age of 18 between 1990 and 2014. Twenty institutions participated. A total of 180 patients were identified. The median age at diagnosis was 5.8 years old and median duration of observation was 8.3 years. Although six patients (3%) deteriorated into the dilated phase of HCM, no patient received heart transplantation. Freedom from death at 1, 5, 10, and 20 years were 97%, 92%, 84%, and 80%, respectively. There were 26 deaths. Among them, 11 patients died suddenly, presumably due to arrhythmia, and 15 patients died of heart failure. The presence of heart failure symptoms and a greater cardiothoracic ratio were significant risk factors for heart failure-related death. There were no significant risk factors identified for arrhythmia-related death. In conclusion, the prognosis of pediatric HCM in Japan is good and similar to those reported in population-based studies in the United States and Australia. Significant risk factors for heart failure-related death were identified in pediatric patients with HCM in Japan.

Keywords: Children; Hypertrophic cardiomyopathy; Mortality; Risk factors.

Publication types

  • Multicenter Study
  • Observational Study

MeSH terms

  • Arrhythmias, Cardiac / complications
  • Cardiomyopathy, Hypertrophic* / complications
  • Cardiomyopathy, Hypertrophic* / diagnosis
  • Cardiomyopathy, Hypertrophic* / therapy
  • Child
  • Child, Preschool
  • Heart Failure* / epidemiology
  • Heart Failure* / etiology
  • Heart Failure* / therapy
  • Humans
  • Japan / epidemiology
  • Retrospective Studies